The study published in the New England Journal of Medicine found nearly 100% survival with adjuvant paclitaxel and trastuzumab.
Patients with small, node-negative, HER2-positive breast cancers had a 3-year survival approaching 100% with adjuvant paclitaxel and trastuzumab (Herceptin), a multicenter, prospective trial showed.
The 406 patients included in the study had 3-year invasive disease-free survival (IDFS) of 98.7%. After excluding contralateral HER2-negative recurrences and nonbreast cancers, investigators identified seven disease-specific recurrences.
Safety results were generally good, as relatively few patients had grade 3 peripheral neuropathy, heart failure, or asymptomatic declines in left ventricular ejection fraction (LVEF), as reported online in the New England Journal of Medicine.
Link to the complete article on Medpage Today: http://bit.ly/1BPBva4